Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells.
about
Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysisNeuroendocrine differentiation in prostate cancerMolecular pathology of prostate cancerPhenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cellsAngiogenesis and prostate cancer tumor growth.The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostatesBlood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer.Clinical implications of neuroendocrine differentiation in prostate cancer.The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice.Angiogenesis as a strategic target for prostate cancer therapy.Angiogenesis and lymphangiogenesis of gastric cancer.Molecular pathways in prostate cancer.Neuroendocrine differentiation of prostate cancer: a review.Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.Distribution of Neuroendocrine Cells in the Transition Zone of the ProstateExpression of the xenobiotic- and reactive oxygen species-detoxifying enzymes, GST-pi, Cu/Zn-SOD, and Mn-SOD in the endocrine cells of colorectal cancer.Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells.Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals.Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP.Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo.Angiogenic factors expressed by human prostatic cell lines: effect on endothelial cell growth in vitro.Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.Immunohistochemical Expression of Angiogenic Factors by Neoplastic Epithelial Cells Is Associated With Canine Prostatic Carcinogenesis.Expression of androgen receptor and growth factors in premalignant lesions of the prostate.Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate.Role of vascular endothelial growth factor in clinically localized prostate cancer treated with radiation therapy.Neuroendocrine tumor cells in prostate cancer: evaluation of the neurosecretory products serotonin, bombesin, and gastrin - impact on angiogenesis and clinical follow-up.A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis.Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins.Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration.Angiogenesis inhibitors in the treatment of prostate cancer
P2860
Q24551021-E099BE28-5536-4973-84C9-5AB7C16CC6D8Q24657547-F8076A99-41F5-42E1-BA2A-6296767BE803Q24672410-365FC093-18B9-4C19-939B-FF2940C06D80Q28360372-9739E826-88BA-4D41-B94F-02103B98AE6AQ30312026-1366860A-A69E-425C-BB79-26C90DDD31A8Q33986252-BE92142A-C02D-4764-9809-C831538F5F03Q34534087-8AA181B9-CA5B-4EB0-ADB3-427D9CEC9513Q36639877-D6C2E289-3F23-43CF-B4EA-38559F96F23FQ37137946-F49EB190-A78A-4F80-9F55-CA9D44D89414Q37523607-00663E1F-9E35-4122-AF09-26EE9D4C7A36Q37724639-D36CDDFD-8522-484B-BD7A-411314DEDED5Q38166735-73B2AB1C-BBF5-4915-AB93-F014FEBF2EF5Q38326554-6299D694-0B8A-4BB8-B782-EB3BA5D0697FQ38586188-C98EC672-4088-44D2-9D55-C5F27817BAEEQ39203734-044FC640-5EA0-4C50-8828-05475F2C9616Q39666772-80505E55-1DF5-452C-81A7-A5308FC4BDFBQ40018064-0F46356C-4BC7-45B5-9118-569CCD6197DFQ40262420-5B50B6A8-1B38-4016-9903-6CB11CD17E59Q40337234-4438BD3C-0538-4F51-992B-CDEC91E36788Q40420012-B63E0CA0-9FBE-4AFA-9638-87968DDDC15FQ41051413-6D724DB0-0A4A-44BE-94B5-ABA50D32C2AAQ41088280-C4AAD651-3686-4F98-BE62-93F173C6C3EEQ41778639-580EE8BC-C644-4DF1-8411-2FB0A22DB797Q42466619-FE7F0D25-E8CE-4A49-B099-1E6A7C050520Q42467183-ABD9C2EB-EF72-4FA7-8766-986EB38BCDEBQ42492515-B2200CB7-47B3-42FC-AE0A-6830215AE66CQ42520039-0AF70A34-7BB1-4EE6-BB76-85632FD804C5Q42757412-7919A090-40BF-4C8B-A9BF-61A3BC82C952Q43756365-CD0513B9-BF6C-44BD-839E-A4A9527CAF2FQ46838377-99CA93E0-1352-4942-A8F1-BB18701CF7A1Q46876140-C6A7ABC0-F367-4C69-A2EB-5E5EAD504A26Q47878234-6C1B2FF5-4EA3-4AC4-A1C0-3303CAE993E8Q57139434-F1D45547-ED1C-4E01-BA9F-18E44041323A
P2860
Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Vascular endothelial growth fa ...... nship to neuroendocrine cells.
@en
type
label
Vascular endothelial growth fa ...... nship to neuroendocrine cells.
@en
prefLabel
Vascular endothelial growth fa ...... nship to neuroendocrine cells.
@en
P2093
P2860
P356
P1476
Vascular endothelial growth fa ...... nship to neuroendocrine cells.
@en
P2093
Glynne-Jones E
Griffiths K
Thurston VJ
P2860
P2888
P304
P356
10.1038/BJC.1996.456
P407
P577
1996-09-01T00:00:00Z